Pain's Remoxy Skips Over Panel On Rocky Road To Market
Executive Summary
The FDA's decision not to hold an advisory committee meeting for Pain Therapeutics Inc.'s twice-before rejected Remoxy looks to bode well for the abuse-deterrent, extended-release oxycodone product – or at least, investors thought so.
You may also be interested in...
Pain Therapeutics Confident It Has US Approval Pathway Set For Remoxy ER
Biotech says it can complete two FDA-mandated studies by year-end and re-file the NDA rejected three times previously by the US agency. Pain Therapeutics also says it will not attempt to commercialize the abuse-deterrent opioid product without a partner.
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
FDA's complete response letter includes extensive list of new studies needed to support abuse-deterrence claims not featured in two prior CRLs, Pain Therapeutics says, wondering why the agency is only now raising issues that could have been discussed previously.
Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review
Pending arrival of several new products prompts evaluation of class, ICER CSO Dan Ollendorf explains; availability of both abuse-deterrent and non-abuse-deterrent drugs among challenging issues.